drugset / Trial / NCT02173795
Berodual® Respimat® Versus Berodual® Metered Aerosol (MA) Inhaler in Patients With Asthma, Chronic Obstructive Pulmonary Disease, or Mixed Condition
RandomizedCrossoverOpen-labelTreatment
Summary
The primary objective of this study was to investigate patients acceptability / preference of Berodual® Respimat® inhaler as compared to the conventional Berodual® Metered Aerosol (MA) inhaler. Ease of handling and assembling the Respimat® inhaler at home under real life conditions was also evaluated.
Timeline
- Start
- 2002-10
- Primary completion
- 2003-06
- Completion
- —
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fenoterol | Unknown | 50 ug | Inhaled |
| Subject | Fenoterol | Unknown | 50 ug | — |
| Subject | Ipratropium | Small molecule | 20 ug | Inhaled |
| Subject | Ipratropium | Small molecule | 20 ug | — |